secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2022-05-04T23:59:59+00:00
Accession:  0001737287-22-000033
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene reports Q1 net loss $79.9M, cash $733M; plans pivotal ALLO-501A trial mid-2022
--------------------------------------------------------------------------------

- Net loss $79.9M ($0.56/sh); R&D $60.2M, G&A $19.9M; cash $733.1M at March 31, 2022.
- Pivotal Phase 2 ALPHA2 trial of ALLO-501A in R/R large B cell lymphoma to start mid-2022 using CF1 product.
- FDA granted Orphan Drug Designation for ALLO-605 (TurboCAR) for multiple myeloma; Fast Track for ALLO-316 for RCC.
- Full-year 2022 GAAP OpEx guided at $360-390M, including $90-100M stock-based compensation.
- Cell Forge 1 operational; projected annual capacity of ~20,000 AlloCAR T doses at scale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728722000033/0001737287-22-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728722000033/allo-20220504.htm
  HTML page:      https://secwatch.observer/filing/0001737287-22-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer